Orapani

Olaparib is already used to treat tumors with BRCA mutations, such as ovarian, breast and prostate cancers. In addition, Olaparib was selective in inhibiting ATM-deficient tumor cells, suggesting that Olaparib could be used as a potential agent for treating ATM-mutated lymphatic tumors.